Structure-guided selection of Specificity Determining Positions in the human kinome

It is well-known that inhibitors of protein kinases bind with very different selectivity profiles. This is also the case for inhibitors of many other protein families. A better understanding of binding selectivity would enhance the design of drugs that target only a subfamily, thereby minimizing possible side-effects. The increased availability of protein 3D structures has made it possible to study the structural variation within a given protein family. However, not every structural variation is related to binding specificity. We propose a greedy algorithm that computes a subset of residue positions in a multiple sequence alignment such that structural and chemical variation in those positions helps explain known binding affinities. By providing this information, the main purpose of the algorithm is to provide experimentalists with possible insights into how the selectivity profile of certain inhibitors is achieved, which is useful for lead optimization. In addition, the algorithm can also be used to predict binding affinities for structures whose affinity for a given inhibitor is unknown. The algorithm's performance is demonstrated using an extensive dataset for the human kinome, which includes a large and important set of drug targets. We show that the binding affinity of 38 different kinase inhibitors can be explained with consistently high precision and accuracy using the variation of at most six residue positions in the kinome binding site.

[1]  Dariya S. Glazer,et al.  The FEATURE framework for protein function annotation: modeling new functions, improving performance, and extending to novel applications , 2008, BMC Genomics.

[2]  Allan Wissner,et al.  Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.

[3]  Lei Xie,et al.  Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments , 2008, Proceedings of the National Academy of Sciences.

[4]  R. Geney,et al.  Type II kinase inhibitors: an opportunity in cancer for rational design. , 2013, Anti-cancer agents in medicinal chemistry.

[5]  Russ B. Altman,et al.  Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding , 2011, PLoS Comput. Biol..

[6]  Alfonso Valencia,et al.  Protein interactions and ligand binding: From protein subfamilies to functional specificity , 2010, Proceedings of the National Academy of Sciences.

[7]  G. Dunteman.  Principal Components Analysis , 1989 .

[8]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[9]  Lydia E. Kavraki,et al.  Improving the Prediction of Kinase Binding Affinity Using Homology Models , 2013, BCB.

[10]  S. Chakrabarti,et al.  Analysis and prediction of functionally important sites in proteins , 2007, Protein science : a publication of the Protein Society.

[11]  Ian Sillitoe,et al.  FLORA: A Novel Method to Predict Protein Function from Structure in Diverse Superfamilies , 2009, PLoS Comput. Biol..

[12]  Lydia E. Kavraki,et al.  The LabelHash algorithm for substructure matching , 2010, BMC Bioinformatics.

[13]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Andreas Christmann,et al.  Support vector machines , 2008, Data Mining and Knowledge Discovery Handbook.

[15]  Barry Honig,et al.  VASP: A Volumetric Analysis of Surface Properties Yields Insights into Protein-Ligand Binding Specificity , 2010, PLoS Comput. Biol..

[16]  Lydia E. Kavraki,et al.  Computational Approaches to Drug Design , 1999, Algorithmica.

[17]  Rocco Piazza,et al.  Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Alfonso Valencia,et al.  Phylogeny-independent detection of functional residues , 2006, Bioinform..

[19]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[20]  Bruce Stillman,et al.  Deciphering Protein Kinase Specificity through Large-scale Analysis of Materials Supplemental Deciphering Protein Kinase Specificity through Large-scale Analysis of Yeast Phosphorylation Site Motifs , 2010 .

[21]  Richard M. Jackson,et al.  Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family , 2009, J. Chem. Inf. Model..

[22]  E. Kellenberger,et al.  A simple and fuzzy method to align and compare druggable ligand‐binding sites , 2008, Proteins.

[23]  Mona Singh,et al.  Characterization and prediction of residues determining protein functional specificity , 2008, Bioinform..

[24]  Li Xing,et al.  Kinase hinge binding scaffolds and their hydrogen bond patterns. , 2015, Bioorganic & medicinal chemistry.

[25]  Ting Zhou,et al.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis , 2010, Bioinform..

[26]  L. Holm,et al.  The Pfam protein families database , 2005, Nucleic Acids Res..

[27]  Eyke Hüllermeier,et al.  Functional Classification of Protein Kinase Binding Sites Using Cavbase , 2007, ChemMedChem.

[28]  Lenore Cowen,et al.  Matt: Local Flexibility Aids Protein Multiple Structure Alignment , 2008, PLoS Comput. Biol..

[29]  M. Gerritsen,et al.  EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation , 2008, Clinical Cancer Research.

[30]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[31]  Andrew E. Firth,et al.  GLUE-IT and PEDEL-AA: new programmes for analyzing protein diversity in randomized libraries , 2008, Nucleic Acids Res..

[32]  M. Gelfand,et al.  Automated selection of positions determining functional specificity of proteins by comparative analysis of orthologous groups in protein families , 2004, Protein science : a publication of the Protein Society.

[33]  Francesca Milletti,et al.  Targeted kinase selectivity from kinase profiling data. , 2012, ACS medicinal chemistry letters.

[34]  Ethan A Merritt,et al.  Sequence determinants of a specific inactive protein kinase conformation. , 2013, Chemistry & biology.

[35]  Richard A. Engh,et al.  Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches. , 2015, Biochimica et biophysica acta.

[36]  Eric Vangrevelinghe,et al.  Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.

[37]  Raquel Cardoso de Melo Minardi,et al.  Identification of subfamily-specific sites based on active sites modeling and clustering , 2010, Bioinform..

[38]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[39]  Lydia E. Kavraki,et al.  Combinatorial Clustering of Residue Position Subsets Predicts Inhibitor Affinity across the Human Kinome , 2013, PLoS Comput. Biol..